Solid Tumor Program
Our Pediatric Solid Tumor Program provides specialized evaluation, diagnosis and care for children, teens and young adults with solid tumors, including neuroblastoma, hepatoblastoma, bone and soft tissue sarcomas, Wilms' tumors and other cancers. We also care for patients whose cancers have relapsed. Our team is known globally for taking on rare and challenging cases.
At UCSF, we believe cancer therapy works best when it is tailored to each patient's disease. Every one of our patients is unique, and our program offers high-quality, targeted care that is precise, effective and compassionate. We evaluate patients using the most advanced diagnostic tools, including genetic tests developed here at UCSF and not offered at other hospitals. Our patients also have access to new treatments that aren't widely available or that are still being evaluated in clinical trials. We're the only hospital in Northern California that's a member of the Oncology Group Phase 1/Pilot Consortium, a small group of leading institutions tasked by the National Cancer Institute with developing new therapies for pediatric cancers.
Our team understands that cancer treatment is an intensely personal experience for each child and family. That's why we draw on the expertise of nurse practitioners, psychologists, social workers and child life specialists to ensure that you and your child receive the support you need. It's also why we strive to make as much of your child's care as possible happen close to home – through telehealth and collaboration with health care providers in your community.
Our locations (1)
Our team
-
Robert E. Goldsby
MD
Hematology and Medical Oncology, Medical Oncology -
Arun Rangaswami
MD
Pediatric Hematology-Oncology -
Amit J. Sabnis
MD, MS
Hematology and Medical Oncology, Medical Oncology -
Alejandro Sweet-Cordero
MD
Hematology and Medical Oncology, Medical Oncology -
Kieuhoa T. Vo
MD
Hematology and Medical Oncology, Medical Oncology -
Cynthia Burke
NP
Pediatric Hematology-Oncology -
Fabienne Hollinger
NP
Pediatric Hematology-Oncology
Awards & recognition
-
Best in Northern California and top 10 in the nation for cancer care
-
Ranked among the nation's best in 11 specialties
-
patients treated with MIBG therapy, a leading-edge neuroblastoma treatment
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
Related clinics (7)
Precision Cancer Medicine Program
7
Hematology Clinic
Orthopedic Surgical Oncology Clinic
2
Bone Marrow Transplant, Cellular and Gene Therapy Program
Support services
Clinical trials
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Determine the overall, pulmonary, structural, and biochemical response rate to selpercatinib in patients with RET fusion differentiated thyroid cancer treated with 6 months of selpercatinib prior to 131I therapy
Recruiting
More about this studyThoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarco...
Estimated four year thoracic event free survival (tEFS) where tEFS is calculated as the time from study enrollment to thoracic cavity event. Any recurrence within the pulmonary parenchyma, involving the pleural surface or the drai...
Recruiting
More about this studyProject: Every Child for Younger Patients With Cancer
The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue saved for future research.
Recruiting
More about this studyTesting the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk N...
EFS time is calculated from date of randomization or assignment to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.
Recruiting
More about this studyTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Adva...
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations).
Recruiting
More about this studyChemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusi...
The Kaplan-Meier method will be used to estimate 3-year FFS along with 80% log-minus-log transformed confidence limits for very low risk (VLR) patients.
Recruiting
More about this studyDinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Child...
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.
Recruiting
More about this studyTesting a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma...
Response rates at the end of Cycle 2 will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method. Any eligible type II/III patient...
Recruiting
More about this studyA Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone...
Feasibility Measures: Patients evaluable for toxicity in the safety run-in must receive one dose of N-803. The proportion of evaluable patients who successfully complete the protocol-defined treatment regimen in the Safety Run-in ...
Recruiting
More about this studyTegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and D...
The number of patients experiencing a cycle 1 dose limiting toxicity at least possibly attributable to tegavivint by study part and dose level.
Recruiting
More about this studyOur research initiatives
Staff superheroes
It’s a bird. It’s a plane. It’s a window washer! Dressed as a superhero to clean and brighten your day.
